Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Evolent Health Inc (NYSE: EVH) closed at $9.97 down -10.82% from its previous closing price of $11.18. In other words, the price has decreased by -$10.82 from its previous closing price. On the day, 6.96 million shares were traded. EVH stock price reached its highest trading level at $11.49 during the session, while it also had its lowest trading level at $9.93.
Ratios:
For a deeper understanding of Evolent Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.61. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.04. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
On December 03, 2024, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $36 to $29.
Stephens Downgraded its Overweight to Equal-Weight on November 08, 2024, whereas the target price for the stock was revised from $38 to $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 22 ’24 when McCarthy Daniel Joseph sold 23,693 shares for $30.89 per share. The transaction valued at 731,790 led to the insider holds 198,809 shares of the business.
McCarthy Daniel Joseph sold 10,469 shares of EVH for $339,008 on Aug 23 ’24. The PRESIDENT now owns 188,340 shares after completing the transaction at $32.38 per share. On Aug 22 ’24, another insider, Weinberg Jonathan, who serves as the General Counsel of the company, sold 42,140 shares for $31.20 each. As a result, the insider received 1,314,706 and left with 167,027 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EVH now has a Market Capitalization of 1146809216 and an Enterprise Value of 1872601472. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.47 while its Price-to-Book (P/B) ratio in mrq is 1.10. Its current Enterprise Value per Revenue stands at 0.76 whereas that against EBITDA is 15.233.
Stock Price History:
The Beta on a monthly basis for EVH is 1.46, which has changed by -0.6253351 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, EVH has reached a high of $35.00, while it has fallen to a 52-week low of $10.53. The 50-Day Moving Average of the stock is -23.82%, while the 200-Day Moving Average is calculated to be -55.58%.
Shares Statistics:
For the past three months, EVH has traded an average of 2.63M shares per day and 1761190 over the past ten days. A total of 115.01M shares are outstanding, with a floating share count of 112.74M. Insiders hold about 3.28% of the company’s shares, while institutions hold 110.96% stake in the company. Shares short for EVH as of 1735603200 were 10194908 with a Short Ratio of 3.88, compared to 1732838400 on 10506932. Therefore, it implies a Short% of Shares Outstanding of 10194908 and a Short% of Float of 10.11.
Earnings Estimates
Evolent Health Inc (EVH) is currently under the scrutiny of 12.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.22, with high estimates of $0.3 and low estimates of $0.16.
Analysts are recommending an EPS of between $0.87 and $0.43 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is $0.92, with 12.0 analysts recommending between $1.24 and -$0.16.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $652.46M this quarter.It ranges from a high estimate of $666.54M to a low estimate of $641.75M. As of the current estimate, Evolent Health Inc’s year-ago sales were $556.05MFor the next quarter, 15 analysts are estimating revenue of $709.8M. There is a high estimate of $752.67M for the next quarter, whereas the lowest estimate is $663.78M.
A total of 15 analysts have provided revenue estimates for EVH’s current fiscal year. The highest revenue estimate was $2.57B, while the lowest revenue estimate was $2.55B, resulting in an average revenue estimate of $2.56B. In the same quarter a year ago, actual revenue was $1.96BBased on 15 analysts’ estimates, the company’s revenue will be $2.87B in the next fiscal year. The high estimate is $3.09B and the low estimate is $2.06B.
